Prior to
publication, the information contained within this announcement was
deemed by the Company to constitute inside information as
stipulated under the UK Market Abuse Regulation. With the
publication of this announcement, this information is now
considered to be in the public domain.
21 June
2024
Braveheart Investment Group plc
("Braveheart", the "Company" or the "Group")
Final Results for the year ended 31 March
2024
Braveheart Investment Group
plc (AIM: BRH) announces its audited annual results for the
financial year ended 31 March 2024, highlights of which are set out
below:
· Loss
per share of 11.38 pence per share (2023: 2.68 pence earnings per
share)
· Cash
balance as at 31 March 2024 of £1.74 million (2023: £0.93
million)
· Pre-tax
loss of £8.19 million (2023: profit of £2.36 million).
Notice of
AGM
A copy of the annual report and accounts,
together with notice of the Company's annual general meeting
("AGM") to be held on 18 July 2024 at 10.30 am at the office of
China Ventures Ltd, Unit 2, Common Farm, Common Lane, Mappleborough
Green, Warwickshire, B80 7DP, will be posted to shareholders
shortly and available on the Company's website,
www.braveheartgroup.co.uk.
For further information:
Braveheart
Investment Group plc
|
Tel: 01738 587555
|
Trevor
Brown, Chief Executive Officer
Viv
Hallam, Executive Director
|
|
|
|
Allenby
Capital Limited (Nominated Adviser and Joint
Broker)
|
Tel: 020 3328 5656
|
James Reeve / George Payne
|
|
|
|
Peterhouse
Capital Limited (Joint Broker)
|
Tel: 020 7469 0936
|
Duncan Vasey / Lucy
Williams
|
|
CHIEF EXECUTIVE
OFFICER'S REPORT
Despite the challenging conditions in the economy and
capital markets, our strategy remains unchanged: to invest
shareholder funds in businesses that we believe possess specific
characteristics capable of generating exceptional returns on
disposal.
On 15 May 2024, Braveheart announced that following a
review of the value of Braveheart's portfolio investments, a
decision had been made to write down the value of the Company's
equity investments in Paraytec Limited ("Paraytec") (book value at
31 March 2023: £3.04m) and Kirkstall Limited ("Kirkstall") (book
value at 31 March 2023: £1.67m) to zero in the FY2024 Accounts and
this has now been implemented following the completion of the
audit. The Board believes that, with time, Paraytec and Kirkstall
could have the potential to increase in value and thereby provide
exit opportunities for the Company.
The Board has also implemented a range of actions to
rationalise the Company's cost base and to conserve cash, which
stood at approximately £1.74 million on 31 March 2024. These
actions include reducing operational overheads and management costs
to reflect the changing needs of the business.
Strategic Investments Overview
Phasefocus
Holdings Limited (now exited)
On 22 December 2023, Braveheart announced the sale
of its entire shareholding in Phasefocus Holdings Limited to Bruker
UK Limited, a global analytical instrumentation company. The total
proceeds received by Braveheart on 31 March 2024 was £2.1m. A
further £53k was received on 27 April 2024, following preparation
of the Completion Accounts, which was a £53k increase on the figure
provided in the announcement of 4 March 2024.
Paraytec
Limited (Braveheart
owns 100% per cent of the company)
Paraytec develops high performance specialist
detectors for the analytical and life sciences instrumentation
markets. During the period it undertook a programme with
the University of Sheffield to develop rapid tests
("CX300") for identifying pathogens, including viruses and bacteria
that cause sepsis. On 2 May 2023, the CX300 instrument passed
independent testing for CE marking, which certifies its compliance
with required safety standards for a laboratory use instrument.
Paraytec continues to develop the CX300 instrument
to assist in the rapid diagnosis and treatment of
bacteraemia, the presence of bacteria in the blood, which is
found in most patients with sepsis and on 15 December 2023, the
Company announced that Paraytec had demonstrated proof-of-concept
for the test, using its CX300 instrument.
On 4 March 2024, the Company announced that, having
used an M&A specialist to market the company and seek a cash
buyer for Paraytec, Braveheart was unable to secure an attractive
offer from potential acquirers, most of those interested felt the
business was at "too early stage". The Board therefore decided to
retain Paraytec within its investment portfolio and continue its
development of the sales and marketing of the CX300 instrument,
with the aim of further enhancing the appeal to a potential
acquirer by offering it for sale at a later development stage.
The current CX300 instrument performs exceptionally
well in detecting and counting particles labelled with a single
colour fluorescent marker. Development is now in progress on the
next generation instrument that will allow two populations of
differently coloured particles to be compared in real time. This
two-colour instrument will give Paraytec
access to a much bigger market, and customer
feedback has indicated that it could be useful for many biomedical
and research applications. Paraytec has recently completed building
its first two-colour instrument prototype, and testing and
miniaturization are now underway. In response to user requests,
Paraytec are also exploring adding further features, such as
back-scatter light measurement to provide researchers more detail
about the particle size.
User testing of the two-colour instrument at
collaborating universities is expected to commence in three months
and it is hoped that marketing and sales will commence
thereafter.
Work continues on the development of a
patentable point-of-care test for bacteraemia that uses CX300
technology to rapidly distinguish between gram-positive and
gram-negative bacteria. Using the same principle as the original
Gram stain, the test uses a genetically engineered fluorescent
protein that binds specifically to peptidoglycan present in
gram-positive but not gram-negative bacteria.
Whilst significant progress in product
development and commercialisation has been made in this period, the
technical challenges encountered delayed product launch. Initial
CX300 instrument sales have now been made, but the original sales
targets have not been met. Following feedback from the M&A
specialist, Braveheart has now concluded that Paraytec should
restrict any significant further investment in product development
until the CX300 has had time to establish its performance
credentials with users in the marketplace.
On 15 May 2024, Braveheart reported
that the Board had concluded that
Paraytec's short-term prospects have
reduced and it no longer
believes that Braveheart's outstanding
loans to Paraytec (totalling £1.44 million
as at 31 March 2024), will be repaid
in the short-term. A decision has therefore
been made to write down the value of the
Company's equity investments and loan
receivable in Paraytec to zero.
Kirkstall
Limited (Braveheart owns 86.11% of the
company)
Kirkstall operates in the market
known as 'organ-on-a-chip', where it has developed Quasi Vivo®, a
system of chambers for cell and tissue culture in laboratories. Its
patented technology is used by researchers in the growing New
Approach Methodologies ("NAMs"), which enable human-relevant drug
safety decisions to be made without the need for animal
testing.
The work at Oxford University to
develop blood-brain barrier assays for Kirkstall was successful.
This work provided data to show that the QV1200 system replicates
the human physiology more effectively than non-flow systems and
these findings have been presented by Kirkstall at
conferences.
Kirkstall received several
enquiries for its contract research organisation (CRO) service,
however after careful assessment it was concluded the costs would
exceed expected returns and so this project has been
concluded.
Kirkstall's QV1200 product is in
use globally within university research teams and has gained much
positive feedback. Kirkstall are collaborating with these
researchers to generate published papers and thus grow sales.
Kirkstall is also in discussion with potential distributors who may
be able to increase the volume of sales over that achieved by
direct sales from the Company. The aim of all this current activity
is to grow revenue to make it more attractive to acquirers and
allow Braveheart to attract a buyer for this business.
On 15 May 2024 Braveheart reported that
Kirkstall has been unable to achieve certain
sales milestones and discussions with M&A
advisers and potential acquirers have not progressed.
Braveheart has concluded that it should restrict further
investment in product development and focus on growing sales to
build a user-base and community of practice in the research
marketplace. Therefore, the Board no longer
believes that Braveheart's outstanding loans to Kirkstall
(totalling £0.16 million as at 31 March 2024), will be repaid in
the short-term. A decision has therefore been made to write down
the value of the Company's
equity investments and loan receivable in
Kirkstall to zero.
The Board believes
that,
with time, both Kirkstall and Paraytec
could have the potential to
increase in value and provide exit opportunities for the Company, but it is prudent to write the
values down to zero at the current time.
Listed Investments
At 31 March 2024, Braveheart held
investments in the following AIM listed companies:
Aukett Swanke Group plc
(Braveheart owned 8.98% of the company) a professional services
group that principally provides architectural, interior design and
smart building services in the primary international market sectors
of offices, residential, education, industrial, hospitality and
mixed use or 'hybrid' developments. On 21 March 2024, Aukett
Swanke announced its acquisition of RTS Technology
Solutions
Limited, so this architectural
services group now includes subsidiaries that provide smart
building software sales and smart building system installation
services.
Autins Group plc (Braveheart
owned 23.96%) an industry-leading designer, manufacturer, and
supplier of acoustic and thermal insulation solutions for the
automotive industry and other sectors. As stated in our
announcement of 6 March 2024, the growth of electric vehicle
production has created new opportunities for Autins who now supply
vehicle producers including: JLR, Nissan, BMW, Aston Martin, Lotus,
Lamborghini and Bentley; as well as Tier 1 automotive suppliers:
Draxlmaier, Kasai, Treves, Novares, Mergon and Yangfeng.
Image Scan Group plc (Braveheart owned 4.48%
of the company) a specialist supplier of real-time
X-ray screening systems to the security and industrial inspection
markets. This company recently announced the launch of AI software
to enhance threat recognition in its X-ray scanning products. Also
announcing, a substantial order and framework contract from an EU
MOD customer, for its portable X-ray system for military and
counter-terrorism applications.
The Company also has several
portfolio investments that are smaller scale legacy investments for
which we continue to seek exits where appropriate.
Outlook
The Board will continue to work
with Paraytec and Kirkstall to help them make sales and attract
buyers. It will continue to seek transformative investments in line
with the investing strategy, rationalize costs and conserve its
£1.74 million cash reserve as of 31 March 2024. Proceeds from the
Phase Focus sale will be used to fund new investments, as such the
Board is not recommending a special dividend.
Trevor
Brown
Chief
Executive Officer
Financial Review
During the year, we continued the
comprehensive review of our cost base and continued to reduce the
central costs.
Income Statement
Fee-based revenue was generated by Braveheart
Investment Group Plc. The principal revenue from the Group's
operations comprises investment management fees, with total revenue
during the year being £61,000 (2023: £51,000). Finance income was
£17,000 (2023: £21,000), this being interest on outstanding loan
notes within the directly held portfolio.
As at 31 March 2024, the total number of
directly held investments in the portfolio of Strategic Investments
and the Portfolio Investments was 19 companies (2023: 21).
The fair value of the directly held portfolio was £1,653,000 (2023:
£9,458,000). During the year the group made investments of £532,000
into three companies: Autins Group Plc, Image Scan Holdings Plc and
Phasefocus Holdings Limited.
The group sold its shareholding in Phase Focus
Holdings in the year, resulting in a profit on disposal of
£1,232,000.
Total income for the year ended 31 March 2024,
including realised gains and unrealised revaluation gains and
losses, was a loss of £2,257,000 (2023: £2,958,000 profit)
and impairments of £4,847,000 (2023 £Nil).
The average number of employees remained at
four during the period under review. Employee benefits expense was
£594,000 (2023: £556,000). Other operating and finance costs
decreased to £282,000 (2023: £283,000).
The total loss after tax decreased to
£7,249,000 (2023: £1,585,000 profit), equivalent to a basic loss
per share of 11.38 pence (2023: 2.68 pence profit).
Financial
Position
The Group had net assets of £3,397,000 as at
31 March 2024 (31 March 2023: £10,520,000).
At the year end, the Group had cash balances
of £1,742,000 (2023: £935,000). There were no material
borrowings.
A summary analysis of the Group's performance
is as follows:
|
2024
|
2023
|
|
£'000
|
£'000
|
Investment management revenue and
sales
|
61
|
51
|
Finance income
|
17
|
21
|
Income before portfolio movements
|
78
|
72
|
Profit on disposal of investments
|
1,304
|
171
|
Change in fair value of investments, gain on
disposal of investments and movement in contingent
liability
|
(2,257)
|
2,958
|
Impairment of investments
|
(4,847)
|
-
|
Total income of continuing activities
|
(5,722)
|
3,201
|
Employee benefits expense (including share-
based payments)
|
(594)
|
(556)
|
Impairment of loans in investment
companies
|
(1,595)
|
-
|
Other operating and finance costs
|
(282)
|
(286)
|
Total costs on continuing activities
|
(2,471)
|
(842)
|
(Loss)/ profit before tax -
continuing
|
(8,193)
|
2,359
|
Tax
|
944
|
(774)
|
Total profit and total comprehensive profit for
the year
|
(7,249)
|
1,585
|
|
|
|
Opening cash balance
|
935
|
1,853
|
Investment in portfolio companies
|
(533)
|
(1,529)
|
Proceeds from sale of equity
investments
|
2,513
|
428
|
Funds raised - net of share issue
costs
|
-
|
930
|
Other activities
|
(1,173)
|
(747)
|
Closing cash balance
|
1,742
|
935
|
|
|
|
Net assets
|
3,397
|
10,520
|
Key Performance Indicators
(KPIs)
The KPIs we use to monitor
business performance have been changed in order to better reflect
the emphasis that the Board has placed upon the development of the
Strategic Investments as the best way to increase shareholder value
over the short and medium term. Given the nature of our business,
these KPI's remain as, primarily, financial measures. They
are:
|
2024
|
2023
|
Cash ('£000)
|
1,742
|
935
|
Share price (pence)
|
6.35
|
6.75
|
Income ('£000)
|
61
|
51
|
Value of investments
|
1,653
|
9,458
|
The value of investments has
reduced significantly in the year mainly due to the sale of Phase
Focus Holdings (£2,502,000) and also the reduction in valuations of
Kirkstall (£1,675,000) and Paraytec (£3,038,000).
Principal Risks and
Uncertainties
Through its operations the Group is exposed to a
number of risks. The Group's risk management objectives and
policies are described in the Corporate Governance
Statement. Braveheart is ensuring that all necessary
steps have been taken to maintain the integrity of the Company's
assets and the health and well-being of our
employees.
Section 172
Statement
Section 172 (1) of the Companies Act obliges
the Directors to promote the success of the Company for the benefit
of the Company's members as a whole. This section specifies that
the Directors must act in good faith when promoting the success of
the Company and in doing so, have regard (amongst other things)
to:
a. the likely consequences of any decision in
the long term,
b. the interests of the Company's
employees,
c. the need to foster the Company's business
relationship with suppliers, customers and others,
d. the impact of the Company's operations on
the community and environment,
e. the desirability of the Company maintaining
a reputation for high standards of business conduct, and
f. the need to act fairly between members of
the Company.
The Board of Directors is collectively
responsible for formulating the Company's strategy, which is to
invest in businesses where prospects appear to be exceptional and
deliver growth to its shareholders. Of course, the Board cannot
predict the future but aims to make decisions that it considers are
in the best interest of all shareholders at the time. In the
period, the decision to sell its holding in Phasefocus Holdings
Limited was such a decision, where the Board decided it was in the
best interest of Braveheart to accept the terms offered by the
buyer, rather than continue to hold shares with the likelihood that
further investment in the business would be required.
The Board places equal importance on all
shareholders and strives for transparent and effective external
communications, within the regulatory confines of an AIM-listed
company. The primary communication tool for regulatory matters and
matters of material substance is through the Regulatory News
Service ("RNS"). The Company's website is also updated regularly
and provides further details on the business as well as links to
helpful content such as our latest investor
presentations.
Our employees are one of the primary assets of
our business and will be critical to the future success of the
Company. First and foremost, the Directors strive to ensure a safe
working environment for all its staff and contractors, and we are
proud of our safety achievements in 2023/24. We also seek to reward
employees with remuneration packages which align the interests of
the Company and its shareholders with those of the employees.
Employees are also provided with challenging work and external
training opportunities to ensure their continual
development.
The Directors believe they have acted in the
way they consider most likely to promote the success of the Company
for the benefit of its members as a whole, as required by Section
172 (1) of the Companies Act 2006.
On behalf of the Board
Trevor E
Brown
Chief Executive Officer
20 June 2024
Consolidated Statement of
comprehensive INCOME for the year
ended 31 March 2024
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
2023
|
|
|
Notes
|
£
|
£
|
|
|
|
|
|
|
Revenue from contracts with
customers
|
3
|
60,896
|
50,902
|
|
Change in fair value of
investments
|
10
|
(2,257,293)
|
2,957,665
|
|
Impairment of investments
|
10
|
(4,847,349)
|
-
|
|
Profit on disposal of
investments
|
10
|
1,304,035
|
170,576
|
|
Total income
|
|
(5,739,711)
|
3,179,143
|
|
|
|
|
|
|
Employee benefits
expense
|
5
|
(594,234)
|
(556,146)
|
|
Other operating costs
|
7
|
(278,852)
|
(283,356)
|
|
Total operating costs
|
|
(873,086)
|
(839,502)
|
|
|
|
|
|
Impairment of loans in investment
companies
|
13
|
(1,594,620)
|
-
|
Finance costs
|
6
|
(2,795)
|
(2,154)
|
|
Finance income
|
4
|
16,896
|
21,003
|
|
Total costs
|
|
(2,453,605)
|
(820,653)
|
|
|
|
|
|
|
(Loss)/ profit before tax
|
|
(8,193,316)
|
2,358,490
|
|
|
|
|
|
|
Tax
|
8
|
944,050
|
(773,652)
|
|
|
|
|
|
|
(Loss)/ profit from continuing operations
|
|
(7,249,266)
|
1,584,838
|
|
|
|
|
|
|
|
|
|
|
|
Total (loss)/ profit and total comprehensive loss for the
year
|
|
(7,249,266)
|
1,584,838
|
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
|
Equity holders of the
parent
|
|
(7,249,266)
|
1,584,838
|
|
|
|
(7,249,266)
|
1,584,838
|
|
|
|
|
|
|
Earnings per share
|
|
Pence
|
Pence
|
|
- basic
|
9
|
(11.38)
|
2.68
|
|
- diluted
|
9
|
(11.38)
|
2.68
|
|
|
|
|
|
|
The accompanying accounting policies
and notes form part of these financial statements.
consolidated statement of
financial position as at 31 March
2024
|
|
|
|
|
|
2024
|
2023
|
|
Notes
|
£
|
£
|
ASSETS
|
|
|
|
Non-current assets
|
|
|
|
Property, plant and
equipment
|
12
|
108
|
418
|
Investments at fair value through
profit or loss
|
10
|
1,653,341
|
9,458,324
|
Debtors due in over one
year
|
13
|
-
|
1,155,200
|
|
|
1,653,449
|
10,613,942
|
|
|
|
|
Current assets
|
|
|
|
Trade and other
receivables
|
14
|
105,707
|
64,510
|
Cash and cash equivalents
|
15
|
1,742,315
|
934,861
|
|
|
1,848,022
|
999,371
|
|
|
|
|
Total assets
|
|
3,501,471
|
11,613,313
|
|
|
|
|
LIABILITIES
|
|
|
|
Current liabilities
|
|
|
|
Trade and other payables
|
16
|
(104,145)
|
(149,656)
|
|
|
(104,145)
|
(149,656)
|
Non-current liabilities
|
|
|
|
Deferred taxation
|
17
|
-
|
(944,050)
|
|
|
|
|
Total liabilities
|
|
(104,145)
|
(1,093,706)
|
|
|
|
|
Net
assets
|
|
3,397,326
|
10,519,607
|
|
|
|
|
EQUITY
|
|
|
|
Called up share capital
|
18
|
1,274,469
|
1,274,469
|
Share premium reserve
|
18
|
5,370,711
|
5,370,711
|
Share based payment
reserve
|
|
598,188
|
471,203
|
Retained earnings
|
|
(3,846,042)
|
3,403,224
|
Equity attributable to owners of the Parent
|
|
3,397,326
|
10,519,607
|
Total equity
|
|
3,397,326
|
10,519,607
|
The accompanying accounting policies
and notes form part of these financial
statements.
Consolidated Statement of
CAsh flows for the year ended 31
March 2024
|
|
|
|
|
|
|
|
|
|
|
|
|
2024
|
2023
|
|
|
|
£
|
£
|
Operating activities
|
|
|
|
|
(Loss)/ profit before tax
|
|
|
(8,193,316)
|
2,358,490
|
Adjustments to reconcile profit before tax to net cash flows
from operating activities
|
|
|
|
|
Share based payment
|
|
|
126,985
|
219,223
|
Impairment of loans in investment
companies
|
|
|
1,594,620
|
-
|
Decrease/ (increase) in the fair
value movements of investments
|
|
|
2,257,293
|
(2,957,665)
|
Impairment of investments
|
|
|
4,847,349
|
-
|
Profit on disposal of equity
investments
|
|
|
(1,304,035)
|
(170,576)
|
Depreciation and
amortisation
|
|
|
310
|
378
|
Interest income
|
|
|
(16,896)
|
(21,003)
|
Increase in trade and other
receivables
|
|
|
(44,015)
|
(194,728)
|
Decrease in trade and other
payables
|
|
|
(21,309)
|
(2,305)
|
Cash flow used in operating activities
|
|
|
(753,014)
|
(768,186)
|
|
|
|
|
|
Investing activities
|
|
|
|
|
Proceeds from sale of
investments
|
|
|
2,512,690
|
428,066
|
Purchase of investments
|
|
|
(532,516)
|
(1,529,127)
|
Loans to investments
|
|
|
(436,602)
|
-
|
Interest received
|
|
|
16,896
|
21,003
|
Net
cash flow used in investing activities
|
|
|
1,560,468
|
(1,080,058)
|
|
|
|
|
|
Financing activities
|
|
|
|
|
Funds raised, net of share
issue costs
|
|
|
-
|
930,363
|
Net
cash flow from financing activities
|
|
|
-
|
930,363
|
|
|
|
|
|
Net increase/ (decrease) in cash and
cash equivalents
|
|
|
807,454
|
(917,881)
|
Cash and cash equivalents at the
beginning of the year
|
|
|
934,861
|
1,852,742
|
Cash and cash equivalents at the end of the
year
|
|
|
1,742,315
|
934,861
|
|
|
|
|
|
The accompanying accounting policies
and notes form part of these financial statements.
For non-cash movement in investing
activities, see note 10
Consolidated Statement of
ChAnges in Equity for the year
ended 31 March 2024
|
Called up Share
Capital
|
Share Premium
Reserve
|
Share based payment
Reserve
|
Retained Earnings/
(Deficit)
|
Total
|
|
Total
Equity
|
GROUP
|
£
|
£
|
£
|
£
|
£
|
|
£
|
At
1 April 2022 restated
|
1,044,807
|
4,371,343
|
309,835
|
1,760,531
|
7,486,516
|
|
7,486,516
|
Profit and total comprehensive
profit for the year
Allotment of shares
|
-
229,662
|
-
1,034,118
|
-
-
|
1,584,838
-
|
1,584,838
1,263,780
|
|
1,584,838
1,263,780
|
Cost of shares issued
|
-
|
(34,750)
|
-
|
-
|
(34,750)
|
|
(34,750)
|
Share based payments
|
-
|
-
|
219,223
|
-
|
219,223
|
|
219,223
|
Transfer to retained earnings -
surrender of options
|
-
|
-
|
(57,855)
|
57,855
|
-
|
|
-
|
Transactions with owners, recognised directly in
equity
|
229,662
|
999,368
|
161,368
|
1,642,693
|
3,033,091
|
|
3,033,091
|
At
31 March 2023
|
1,274,469
|
5,370,711
|
471,203
|
3,403,224
|
10,519,607
|
|
10,519,607
|
Profit and total comprehensive
profit for the year
|
-
|
-
|
-
|
(7,249,266)
|
(7,249,266)
|
|
(7,249,266)
|
Share based payments
|
-
|
-
|
126,985
|
-
|
126,985
|
|
126,985
|
Transactions with owners, recognised directly in
equity
|
-
|
-
|
126,985
|
(7,249,266)
|
(7,122,281)
|
|
(7,122,281)
|
At
31 March 2024
|
1,274,469
|
5,370,711
|
598,188
|
(3,846,042)
|
3,397,326
|
|
3,397,326
|
|
|
|
|
|
|
|
|
Share capital is the number of
shares issued in the company at their nominal value. The share
premium account represents the gross proceeds from issue of shares,
less their nominal value. Share based
payment reserve is the amount generated from the award of share
options and warranties. Retained earnings is the cumulative net
gains and losses recognised in the consolidated statement of
comprehensive income net of associated share-based payments
credits.
Notes to the financial
statements for the year ended 31
March 2024
1
Corporate information
The Group and Company financial
statements of Braveheart Investment Group plc (the Company) for the
year ended 31 March 2024 were authorised for issue by the Board of
Directors on 20 June 2024 and the statements of financial position
were signed on the Board's behalf by Trevor Brown.
Braveheart Investment Group plc is
a public company incorporated in the United Kingdom under the
Companies Act 2006 limited by shares. The address of the
registered office is detailed at the back of this report. The
nature of the Group's operations and its principal activities are
set out in the Strategic Report and Directors' Report. The
Company is registered in Scotland. The Company's ordinary
shares are traded on the AIM market of the London Stock
Exchange.
2
Accounting policies
(a) Basis of
preparation
The Group and Company financial
statements have been prepared in accordance with UK-adopted
international accounting standards in accordance with the
requirements of the Companies Act 2006 and in accordance with the
requirements of the AIM rules. The principal accounting policies
adopted by the Group and by the Company are set out
in the following notes.
The consolidated financial
statements have been prepared on a historical cost basis, except
for financial instruments that are measured at the fair values at
the end of the reporting period. The financial statements are
presented in sterling and all values are rounded to the nearest
pound (£), which is also the functional currency of the company and
its subsidiaries, except where otherwise indicated.
The Group's business activities
(together with the factors likely to affect its future development,
performance and position) and its financial position is set out in
the Chief Executive Officer's Report. The
Group's risk management objectives and policies are described in
the Corporate Governance
Statement. Further information regarding the Group's financial risk
management objectives and policies, including those in relation to
credit risk, liquidity risk and market
risk, is provided in note 21 to the
financial statements. The Group's capital
management objectives are stated on page 46, note (n).
(b)
Investment policy
The Group's strategy is to invest in
early and later-stage businesses, primarily in the technology
sector, but it will also consider opportunities in other sectors
that are knowledge intensive, such as healthcare and professional
services.
The Group will target investments in
both unlisted and listed companies, where there is potential for
significant growth. Investments are expected to be mainly in the
form of equity and equity-related instruments, including
convertible debt instruments in certain circumstances.
The Group may acquire
investments directly or by way of holdings in intermediate holding
or subsidiary entities. The Group might also invest in limited
liability partnerships and other forms of legal entity. Where
possible, the Group will seek investor protection rights, as
determined by the Board. The Group may offer its Ordinary Shares in
exchange for shares in investee businesses in addition to a cash
investment in such businesses.
For unlisted company investments,
the Group targets companies at different stages of development,
ranging from those which are just starting to trade to those which
are expecting to achieve an IPO in the short term, thus providing
portfolio diversification. These investments will typically involve
active investment management.
The Group, where appropriate and
deemed by the Board to be in the Group's best interests, may seek a
position on the boards of unlisted investee companies. The Group
where appropriate, will assist the board and management of investee
companies, including helping to scale management teams, informing
strategy and assisting with future financing.
For listed company investments, the
Group targets investments where the Board considers the shares are
undervalued but there are opportunities for significant growth.
These investments will typically involve passive investment
management, although the Board may take a more active approach if
it considers there is a need to effect change.
Braveheart may occasionally invest
in companies that are in rescue or distress situations where a
value-creating opportunity has been identified.
The Group does not have any maximum
exposure limits but will generally take a minority stake in a
business and look for investments where there is a good prospect of
an exit in a two-to-five-year time period. As risk reduces, the
Group may increase its investment in subsequent rounds of funding
and, as those businesses grow, may find itself holding a
controlling interest in some trading companies. However, in such
instances the Board will ensure that there is sufficient separation
between the Group and the investee company so that the investee
company does not become a trading company of the Group.
(c) Going
Concern
The directors have reviewed the
Group's and the Company's budgets and plans, taking account of
reasonably possible changes in trading performance and have a
reasonable expectation that the Group and the Company have adequate
resources to continue in operational existence for the foreseeable
future and that it is therefore appropriate to continue to adopt
the going concern basis in preparing the financial
statements.
Following the sale of Phase Focus
Holdings, the group currently have large bank balances and
undertake regular reviews of the cash flows of the company.
Furthermore, the group have a large number of listed investments
that could be converted to cash if required. The group forecast at
least 12 months into the future at all times in order to ensure
that the company can continue into the foreseeable
future.
(d) Changes in accounting
policy and disclosures
There are no new standards which
became effective in the year which had a material impact on the
group.
(e) New standards and
interpretations not yet effective
The Group has adopted all
recognition, measurement and disclosure requirements of IFRS,
including any new and revised standards and interpretations of
IFRS, in effect for annual periods commencing on or after 1 April
2023. The adoption of these standards and amendments did not have
any material impact on the financial result of position in the
Group.
At the date of authorisation of
these financial statements, the following Standards and
Interpretation, which have not yet been applied in these financial
statements, were in issue, but not yet effective:
New Standards
|
Effective Date
|
IAS 1 Amendments - Presentation
and Classification of Liabilities as Current or Non
current
|
1 January 2024
|
IAS 1 Amendments - Non-current
liabilities with covenants
|
1 January 2024
|
IAS 7 Statement of Cash Flows and
IFRS 7 Financial Instruments: Disclosures: - Supplier Finance
Arrangements
|
1 January 2024
|
(f) Basis of
consolidation
The Group's financial statements
consolidate the results of Braveheart Investment Group plc and its
subsidiaries (together referred to as the 'Group') drawn up to 31
March each year. The financial
statements of the subsidiaries used in the preparation of the
consolidated financial statements are prepared for the same
reporting year as the parent company using consistent accounting
policies. All intra-group balances,
transactions, income and expenses are eliminated in full on
consolidation. The Company is classified as an investment entity as
it meets the definition of an investment entity within Paragraph 27
IFRS 10.
- Subsidiaries
The subsidiaries have been
consolidated from the date of their acquisition, being the date on
which the Group obtained control, and will continue to be
consolidated until the date that such control ceases. As per IFRS
10, an entity is classed as under the control of the Group when all
three of the following elements are present: power over the entity,
exposure to variable returns from the entity and the ability of the
Group to use its power to affect those variable returns. Control is
reassessed whenever facts and circumstances indicate that there may
be a change in any of these elements of control.
A change in the ownership interest
of a subsidiary, without a loss of control, is accounted for as an
equity transaction.
The group applies the acquisition
method to account for business combinations. The consideration
transferred for the acquisition of a subsidiary is the fair values
of the assets transferred, the liabilities incurred to the former
owners of the acquiree and the equity interests issued by the
group. The consideration transferred includes the fair value of any
asset or liability resulting from a contingent consideration
arrangement. Identifiable assets acquired and liabilities and
contingent liabilities assumed in a business combination are
measured initially at their fair values at the acquisition date.
The group recognises any non-controlling interest in the acquiree
on an acquisition-by-acquisition basis, either at fair value or at
the non-controlling interest's proportionate share of the
recognised amounts of acquiree's identifiable net
assets.
Acquisition-related costs are
expensed as incurred.
If the business combination is
achieved in stages, the acquisition date carrying value of the
acquirer's previously held equity interest in the acquiree is
re-measured to fair value at the acquisition date; any gains or
losses arising from such re-measurement are recognised in profit or
loss.
If the Group loses control over a
subsidiary, it derecognises the related assets, liabilities,
non-controlling interest and any other components of equity while
any resultant gain or loss is recognised in profit or loss. Any
investment retained is recognised at fair value.
The Group is made up of several
different types of subsidiaries. The Group assesses the function
performed by each type of subsidiary to determine its treatment
under the IFRS 10 exception from consolidation. The types of
subsidiaries and their treatment under IFRS 10 are as
follows:
·
Investment managers -
Consolidated
These entities provide investment
related services through the provision of investment management or
advice. They do not hold any direct investments in portfolio
assets. These entities are not investment entities.
· General Partners (GPs) - Consolidated
General Partners provide
investment management services and do not hold any direct
investments in portfolio assets. These entities are not investment
entities.
Non-controlling interests represent
the portion of profit or loss and net assets that is not held by
the Group and are presented separately in the consolidated
statement of comprehensive income and within equity in the
consolidated statement of financial position separately from parent
shareholders' equity.
(g) Use of estimates and
assumptions
The preparation of the financial
statements in conformity with IFRS requires management to make
judgements, estimates and assumptions that affect the application
of policies and reported amounts of assets and liabilities, income
and expenses. The estimates and associated assumptions are
based on historical experience and other factors that are believed
to be reasonable under the circumstances, the results of which form
the basis of making the judgements about carrying values of assets
and liabilities that are not readily apparent from other
sources. Actual results may differ from these
estimates. Where management's judgement has been applied,
this is noted in the relevant accounting policy.
The key assumptions concerning the
future and other key sources of estimation uncertainty at the
reporting date that have a significant risk of causing a material
adjustment to the carrying amounts of assets and liabilities within
the next financial year are discussed below:
- Assessment as an
investment entity
Entities that meet the definition of
an investment entity within IFRS 10 are required to account for
most investments in controlled entities at fair value through
profit and loss. The Board has concluded that the Company
continues to meet the definition of an investment entity as its
strategic objective of investing in portfolio investments and
providing investment management services to investors for the
purpose of generating returns in the form of investment income and
capital appreciation remains unchanged.
The Group is required to determine
the degree of control or influence the Group exercises and the form
of any control to ensure that the financial treatment is
accurate.
- Impairment of
investments and loan receivable from investee companies - see
note 10
Management assessment of the
impairment indicators including; performance of the investee
companies, future prospects, ability to exit and based on that
decided to impair investments in Kirkstall (2023: £1,675,000),
Paraytec (2023: £3,038,000), KDS Architecture (2023: £76,000), Ni
Tech (2023: £48,000), and Zilico (2023: £10,000) to
£Nil.
- Fair value of
unquoted investments - see note 10
Unquoted investments have been
valued by the directors in compliance with the principles of the
International Private Equity and Venture Capital Guidelines as
endorsed by the European Venture Capital Association (EVCA).
The use of such valuation techniques requires the directors to make
certain judgements including making assessments of future revenue
and earnings of portfolio companies, appropriate multiples to
apply, and marketability and other risk discounts and provisions,
and hence they are subject to uncertainty. Management believes that
in their experience, the last round share price tends to be the
most reliable method of calculating these investments, unless there
is a major change to the company since that point as there is a
proven basis for the share price. The fair value of unquoted
investments of the Group at 31 March 2024 was £39,246
(2023: £2,574,938) and
of the Parent Company was £39,228 (2023: £2,574,567).
The value of investments has reduced
significantly in the year mainly due to the sale of Phase Focus
Holdings (£2,502,000).
To reflect the potential impact of
alternative assumptions and a lack of liquidity in these holdings,
a discount has been applied to all Level 3 valuations.
Further information regarding the Group's and
Parent Company's fair value of unquoted investments is provided in
note 10
-
Share-based payments
The Group measures the cost of
equity-settled transactions by reference to the fair value of the
equity instruments at the date at which they were granted.
Judgement is required in determining the most appropriate valuation
model for a grant of equity instruments depending on the terms and
conditions of the grant. Management are also required to use
certain assumptions in determining the most appropriate inputs to
the valuation model including expected life of the option,
volatility, risk free rate and dividend yield. The
assumptions and models used are fully disclosed in note
19.
(h) Revenue
recognition and segmental reporting
The Group earns fee income from the
services it provides to its clients and monitoring fees from
investee companies. Revenue is recognised at the fair value of the
consideration received or receivable, excluding rebates. Fees
earned for the provision of an ongoing service are recognised as
that service is provided. Deal fees and arrangement fees are earned
on individual transactions and related revenue is recognised on
completion
of the
underlying transaction. The Group receives compensation for
its role as fund manager; these fund management fees include fixed
fees and performance fees and are recognised as the related
services are provided. Monitoring fees are recognised as that
service is provided.
Interest income is recognised using
the effective interest method. Interest income is interest earned
on bank deposit accounts and loan notes and is included within the
statement of comprehensive income.
Revenue is deferred when it does not
meet the revenue recognition policy and is presented as deferred
income in the statement of financial position.
An operating segment is a component
of the Group that engages in business activity from which it may
earn revenues and incur expenses, including revenues and expenses
that relate to transactions with and of the Group's other
components. All operating segments' operating results, for which
discrete financial information is available, are reviewed regularly
by the Group's Board to make decisions about resources to be
allocated to the segment and assess its performance.
(i)
Taxation
The tax expense represents the sum
of the tax currently payable. Current tax is based on taxable
profit for the year. Taxable profit differs from net profit as
reported in the statement of comprehensive income because it
excludes items of income or expenses that are deductible in other
years and it further excludes items that are never taxable or
deductible. The Group's liability for current tax is
calculated using tax rates that have been enacted or substantively
enacted by the reporting date.
A deferred tax asset or liability
shall be recognised for all taxable temporary differences, except
to the extent that the deferred tax asset or liability arises from
(a) the initial recognition of goodwill, (b) the initial
recognition of an asset or liability in a transaction which (i) is
not a business
combination and (ii) at the time of
the transaction, affects neither accounting profit/(loss) nor
taxable profit/(loss) or (c) relates to an investment in
subsidiary, except to the extent that (i) the parent is able to
control timing of reversal and (ii) it is probable that temporary
differences will not
reverse in the foreseeable
future. Deferred tax assets are recognised to the extent that
it is probable that taxable profits will be available against which
deductible temporary differences can be utilised. Deferred
tax is calculated at the tax rates that are expected to apply in
the period when the liability is settled or the asset is realised
using tax rates and laws that have been enacted or substantively
enacted by the reporting date.
(j) Tangible
assets
Tangible fixed assets are stated at
cost less depreciation and any provision for impairment.
Depreciation is calculated using
the straight-line method to allocate their cost or revalued
amounts, net of their residual values, over their estimated useful
lives as follows:
Furniture, fittings and office
equipment
over three years
(k) Financial
assets
Financial assets are recognised
when the Group becomes party to the contracts that give rise to
them and are classified at initial recognition as either financial
assets at fair value through profit or loss or loans and
receivables. Financial assets are derecognised when the rights to
receive cash flows from the asset have expired or the Group has
transferred substantially all the risks and rewards of the
asset.
- Impairments
Investments are tested for
indicators of impairment on a regular basis. Where an investment
has been deemed to be impaired, that asset is written down
accordingly.
- Investments at
fair value through profit or loss
Investments, which is made up of
equity investments, are designated on initial recognition as
financial assets at fair value through profit or loss. This
measurement basis is consistent with the fact that the Group's
performance in respect of its portfolio investments is evaluated on
a fair value basis in accordance with an established investment
strategy. When investments are recognised initially, they are
measured at fair value.
After initial recognition the fair
value of listed investments is determined by reference to bid
prices at the close of business on the reporting date.
Unlisted equity investments are
measured at fair value by the directors in compliance with the
principles of the International Private Equity and Venture Capital
Guidelines, updated and effective December 2015, as recommended by
the European Venture Capital Association. The fair value of
unlisted equity investments is determined using the most
appropriate of the valuation methodologies set out in the
guidelines. These include
using recent arm's length market
transactions; reference to the current market value of another
instrument, which is substantially the same; earnings or profit
multiples; indicative offers; discounted cash flow analysis and
pricing models.
Wherever possible the Group uses
valuation techniques which make maximum use of observable market
based inputs and accordingly the basis of the valuation methodology
preferred by the Group is 'price of most recent investment'. Where
'price of most recent investment' is no longer considered to be
appropriate, the Group has used valuations based on discounted cash
flow method using business forecasts provided by the investee
company, revenue multiples of comparable listed companies and
comparable transactions.
- Price of recent
investment
The Group considers that fair value
estimates, which are based entirely on observable market data, will
be of greater reliability than those based on assumptions and,
accordingly, where there has been any recent investment by third
parties, the price of that investment will generally
provide
a basis of the valuation. The length
of period for which it remains appropriate to use the price of
recent investment depends on the specific circumstances of the
investment and the stability of the external environment. Given the
nature of the Group's investments in early-stage companies, where
there are often no current and no short-term future earnings or
positive cash flows, it can be difficult to gauge the probability
and financial impact of the success or failure of development or
research activities and to make reliable cash flow forecasts.
Consequently, the most appropriate approach to determine fair value
is a methodology that is based on market data, that being the price
of a recent investment. Where the Group considers that the price of
recent investment, unadjusted, is no longer relevant and there are
limited or no comparable companies or transactions from which to
infer value, the Group carries out an enhanced assessment based on
milestone analysis and/or industry and sector analysis. In applying
the milestone analysis approach to investments in companies in
early or development stages the Group seeks to determine whether
there is an indication of change in fair value based on a
consideration of performance against any milestones that were set
at the time of the original investment decision, as well as taking
into consideration the key market drivers of the investee company
and the overall economic environment.
Where the Group considers that there
is an indication that the fair value has changed, an estimation is
made of the required amount of any adjustment from the last price
of recent investment. Wherever possible, this adjustment is based
on objective data from the investee company and the experience and
judgement of the Group. However, any adjustment is, by its very
nature, subjective. Where a deterioration in value has occurred,
the Group reduces the carrying value of the investment to reflect
the estimated decrease. If there is evidence of value creation
the
Group may consider increasing the
carrying value of the investment; however, in the absence of
additional financing rounds or profit generation it can be
difficult to determine the value that a purchaser may place on
positive developments given the potential outcome and the costs and
risks to achieving that outcome and accordingly caution is applied.
Factors that the Group considers include, inter alia, technical
measures such
as product development phases and
patent approvals, financial measures such as cash burn rate and
profitability expectations, and market and sales measures such as
testing phases, product launches and market
introduction.
In the current financial year, where
'price of recent investment' methodology was used to value the
business, some investments were considered not to be making
significant commercial progress and when a discount was applied to
reflect the non-marketability associated with Braveheart's limited
control of the business, the resulting valuations were
zero.
- Other valuation
techniques
If there is no readily ascertainable
value from following the 'price of recent investment' methodology,
or there is objective evidence that a deterioration or significant
improvement in fair value has occurred since a relevant
transaction, the Group considers alternative methodologies such as
discounted cash flows ("DCF"). DCF involves estimating the fair
value of a business by calculating the present value of expected
future cash flows, based on the most recent forecasts in respect of
the underlying business. Given the difficulty of producing reliable
cash flow forecasts
for early-stage companies as
described earlier, this methodology is used only where it is
considered there is reasonable evidence of current and ongoing
income streams.
- No reliable
estimate
Where a fair value cannot be
estimated reliably, the investment is reported at the carrying
value at the previous reporting date unless there is objective
evidence that the investment has since been impaired.
- Loans and
receivables
Loans and receivables are
non-derivative financial assets with fixed or determinable payments
that are not quoted in an active market, and comprise trade and
other receivables, other financial assets and cash and cash
equivalents, all of which are initially recognised at fair value
and are subsequently measured at amortised cost using the effective
interest rate method. This means that, in cases where repayment of
the loan or other receivable is in doubt, due to the commercial
performance of the recipient, the value of that loan may be
impaired to zero in the accounts.
They are included in current
assets, except for maturity greater than 12 months after the end of
the reporting period, whereby these are classified as non-current
assets.
- Trade
receivables
Trade receivables are initially
recognised at fair value which is normally the invoice value in
short term receivables. Thereafter the receivables are carried at
amortised cost. Provision is made where there is objective evidence
that a balance will not be recovered in full in accordance with the
instrument's original terms. An impairment calculation is based on
a comparison between the carrying amount and the net present
value of expected future cash flows,
discounted by the original effective rate. It can be concluded that any provision calculated would not
have material impact on the financial statements due to the minimal
amount of receivables and a formal policy will be implemented when
necessary.
- Cash and cash
equivalents
Cash and cash equivalents in the
consolidated cashflow comprise cash in hand and short term bank
deposits.
(l) Financial
liabilities
Financial liabilities, being trade
and other payables, are initially recognised at fair value and are
subsequently carried at amortised cost.
(m) The Company's investment
in its subsidiaries
In the Company's accounts,
investment in its subsidiary undertakings are stated at cost less
any provision for impairment.
(n) Equity
Financial instruments issued by
the Group are treated as equity if the holders have only a residual
interest in the Group's assets after deducting all liabilities. The
Group considers its capital to comprise its share capital, share
premium, merger reserve and retained earnings.
· Share premium - amount subscribed for share capital in excess
of nominal value, net of directly attributable issue
costs;
· Retained earnings - cumulative net gains and losses
recognised in the consolidated statement of comprehensive income
net of associated share-based payments credits;
· Share based payment reserve - amount generated from the award
of share options and warranties.
The Group's capital management
objectives are:
· to
ensure the Group's ability to continue as a going
concern;
· to
ensure a sufficient cash balance is maintained; and
· to
maximise returns to shareholders.
The Group continuously monitors
rolling cash flow forecasts to ensure sufficient cash is available
for anticipated cash requirements. The Group may issue new shares
or realise investments to meet such requirements. To date the Group
has negligible borrowings and does not pay a dividend.
Investments made by the Group are subject
to detailed selection criteria and are
monitored carefully by the Board. The group considers that it has
appropriately managed its capital requirements during the
year.
There has been no change in
capital management objectives, policies and procedures from the
previous year.
(o) Share-based
payments
The cost of equity-settled
transactions with employees is measured by reference to the fair
value of the instruments issued at the date at which they are
granted and is recognised as an expense over the vesting period,
which ends on the date on which the relevant employees become fully
entitled to the award. Fair value is determined using an
appropriate pricing model. In valuing equity-settled
transactions, no account is taken of any vesting conditions, other
than conditions linked to the price of the shares of the Company
(market conditions).
No expense is recognised for awards
that do not ultimately vest, except for awards where vesting is
conditional upon a market condition, which are treated as vesting
irrespective of whether or not the market condition is satisfied,
provided that all other performance conditions are
satisfied.
At each reporting date before
vesting, the cumulative expense is calculated, representing the
extent to which the vesting period has expired and management's
best estimate of the achievement or otherwise of non-market
conditions and of the number of equity instruments that will
ultimately vest or, in the case of an instrument subject to a
market condition, be treated as vesting as described above.
The movement in cumulative expense since the previous reporting
date is recognised in the statement of comprehensive income, with a
corresponding entry in equity.
Where the terms of an equity-settled
award are modified or a new award is designated as replacing a
cancelled or settled award, the cost based on the original award
terms continues to be recognised over the original vesting
period. In addition, any expense is recognised over the
remainder of the new vesting period for the incremental fair value
of any modification, based on the difference between the fair value
of the original award and the fair value of the modified award,
both as measured on the date of the modification. No
reduction is recognised if this difference is negative.
Where an equity-settled award is
cancelled, it is treated as if it had vested on the date of
cancellation, and any cost not yet recognised in the statement of
comprehensive income for the award is expensed immediately.
Any compensation paid up to the fair value of the award at the
cancellation or settlement date is deducted from equity, with any
excess over fair value being treated as an expense in the statement
of comprehensive income.
(p) Pensions
The Group makes defined pension
contributions to certain employees of the group. The assets of the
scheme are held separately from those of the Group in independently
administered funds. The Group has no further obligations once the
contributions have been paid. The contributions are recognised as
employee benefits expenses when they are due.
(q) Foreign
currency
Foreign currency exchange gains and
losses resulting from the remeasurement of monetary items
denominated in foreign currency at the year-end exchange rates are
recognised in the statement of comprehensive income.
Foreign currency transactions are translated into
the functional currency using the exchange rates prevailing at the
dates of the transactions. Foreign exchange gains and losses
resulting from the settlement of such transactions and from the
translation at year-end exchange rates of monetary assets and
liabilities denominated in foreign currencies are recognised in the
income statement. Foreign exchange gains and losses are presented
in the income statement within 'finance income or
costs.'
(r) Earnings per
share
Basic earnings per share is
calculated by dividing:
· the
profit attributable to owners of the company, excluding any costs
of servicing equity other than ordinary shares;
· by
the weighted average number of ordinary shares outstanding during
the financial year, adjusted for bonus elements in ordinary shares
issued during the year and excluding treasury shares (note
18).
Diluted earnings per share adjusts
the figures used in the determination of basic earnings per share
to take into account:
· the
after-income tax effect of interest and other financing costs
associated with dilutive potential ordinary shares; and
· the
weighted average number of additional ordinary shares that would
have been outstanding, assuming the conversion of all dilutive
potential ordinary shares.
(s)
Segmental Reporting
The board only considers there to be
one segment in the group and therefore there is no note included
for segmental reporting.
3
Revenue from contracts with customers
Revenue is attributable to the
principal activities of the Group. In 2024 and 2023, all revenue
arose within the United Kingdom.
|
|
|
|
|
|
|
|
|
|
Group
2024
|
Group
2023
|
|
|
|
|
£
|
£
|
Investment management
|
|
|
40,000
|
15,000
|
Monitoring fees
|
|
|
3,600
|
3,600
|
Consultancy
|
|
|
17,296
|
32,302
|
|
|
|
|
60,896
|
50,902
|
Of the revenue stated above, £20,770
(2023: £32,302) related to The Lachesis Seed Fund Limited
Partnership.
The group derives revenue from the
transfer of goods and services over time and at a point in time in
the following major product lines:
|
Investment management
|
Monitoring fee
|
Consultancy
|
Total
|
2024
|
|
|
|
|
|
|
|
|
|
|
|
Timing of revenue
recognition
|
|
|
|
|
|
At a point in time
|
|
|
3,600
|
-
|
3,600
|
Over time
|
40,000
|
|
-
|
17,296
|
57,296
|
|
40,000
|
|
3,600
|
17,296
|
60,896
|
2023
|
|
|
|
|
|
|
|
|
|
|
|
Timing of revenue
recognition
|
|
|
|
|
|
At a point in time
|
|
|
3,600
|
-
|
3,600
|
Over time
|
15,000
|
|
-
|
32,302
|
47,302
|
|
15,000
|
|
3,600
|
32,302
|
50,902
|
4
Finance income
|
|
|
Group
|
Group
|
|
|
|
2024
|
2023
|
|
|
|
£
|
£
|
Bank interest receivable
|
|
|
16,896
|
21,003
|
|
|
|
16,896
|
21,003
|
5
Employee benefits expense
|
|
|
|
|
|
|
|
Company
2024
|
Company
2023
|
Group
2024
|
Group
2023
|
|
|
£
|
£
|
£
|
£
|
Salaries
|
|
427,451
|
306,481
|
427,451
|
306,481
|
Social security costs
|
|
32,018
|
24,568
|
32,018
|
24,568
|
Pension costs
|
|
7,780
|
5,874
|
7,780
|
5,874
|
Share based payments
|
|
126,985
|
219,223
|
126,985
|
219,223
|
|
|
594,234
|
556,146
|
594,234
|
556,146
|
The average number of persons
(including directors) employed by the Group during the year was 5
(2023: 4), all of whom were involved in management and
administrative activities. The average number of persons (including
directors) employed by the company during the year was 4 (2023: 3)
The remuneration of the directors, is set out below in
aggregate:
|
|
|
|
2024
|
2023
|
|
|
|
|
£
|
£
|
Short-term employee
benefits
|
|
|
|
347,452
|
299,814
|
Social security costs
|
|
|
|
22,232
|
23,753
|
|
|
|
|
369,684
|
323,567
|
|
|
|
|
|
|
Post-employment benefit
|
|
|
|
5,380
|
5,674
|
Share-based payments
|
|
|
|
126,985
|
219,223
|
|
|
|
|
502,049
|
548,464
|
The figures in this note includes
social security costs. Further information about the remuneration
of individual directors is provided in the Directors' Remuneration
Report.
Remuneration to the highest paid
director was £148,521 (2023: £135,096). This figure excludes social
security costs.
6
Finance costs
|
|
|
|
Group
|
Group
|
|
2024
|
2023
|
|
£
|
£
|
Bank charges
|
2,795
|
2,154
|
7
Expenses by nature
|
|
|
|
Group
|
Group
|
The following have
been charged in arriving at operating loss:
|
2024
|
2023
|
|
£
|
£
|
Depreciation and
amortisation
|
310
|
378
|
Auditor's remuneration:
Audit services
- Fees payable for the
audit of the consolidation and the parent company
accounts
|
63,450
|
56,700
|
Legal, professional and consultancy
costs
|
42,986
|
49,605
|
Stockbroker costs
|
65,525
|
76,250
|
Other expenses
|
106,581
|
100,423
|
Total
|
278,852
|
283,356
|
8
Tax on profit on ordinary activities
No liability to UK corporation tax
arose on ordinary activities for the year ended 31 March 2024 or
for the year ended 31 March 2023.
|
|
|
|
|
|
Group
|
Group
|
|
|
2024
|
2023
|
Reconciliation of total tax:
|
|
£
|
£
|
(Loss)/ profit before tax
|
|
(8,193,316)
|
2,358,490
|
|
|
|
|
Tax at the statutory rate of 25%
(2023: 19%)
|
|
(2,048,329)
|
448,113
|
Disallowed expenses
|
|
431,762
|
43,288
|
Capital allowances in excess of
depreciation
|
|
78
|
72
|
Unrealised loss/ (gain) on the fair
value movement of investments
|
|
1,468,112
|
(561,705)
|
Share scheme deduction
|
|
-
|
(3,047)
|
Other non-reversing timing
differences
|
|
(944,050)
|
773,652
|
Tax losses carried
forward
|
|
148,377
|
73,279
|
Total tax reported in the statement of comprehensive
income
|
|
(944,050)
|
773,652
|
The Group has
potential cumulative unrecognised deferred tax assets in respect
of:
· excess management expenses of £1,430,874 (2023:
£843,506) arising
from Braveheart Investment Group plc; and
· excess management expenses of £559,199 (2023: £558,768)
arising from Caledonia Portfolio Realisations Limited.
· excess trading loss of £12,564 (2023: £5,701) arising from
The Ridings Early Growth Investment Company Limited.
From April 2023, the corporation
tax rate increased from 19% to 25%.
No deferred tax assets have been
recognised in respect of these amounts as it is uncertain that
there will be suitable taxable profits from which the future
reversal of the deferred tax could be deducted.
9
Earnings per share
Basic earnings per share has been
calculated by dividing the profit attributable to equity holders of
the parent by the weighted average number of ordinary shares in
issue during the year.
The calculations of profit per share
are based on the following profit and numbers of shares in
issue:
|
|
|
|
2024
|
2023
|
|
£
|
£
|
(Loss)/ profit for the
year
|
(7,249,266)
|
1,584,838
|
|
|
|
Weighted average number of ordinary
shares in issue:
|
No.
|
No.
|
For basic profit per ordinary
share
|
63,723,489
|
59,104,950
|
Potentially dilutive ordinary
shares
|
-
|
-
|
For diluted earnings per ordinary
share
|
63,723,489
|
59,104,950
|
Earnings per share
|
|
Pence
|
Pence
|
- basic
|
9
|
(11.38)
|
2.68
|
- diluted
|
9
|
(11.38)
|
2.68
|
Dilutive earnings per share adjusts
for share options granted where the exercise price is less than the
average price of the ordinary shares during the period. At
the current year end there were Nil (2023: Nil) potentially
dilutive ordinary shares.
The diluted earnings per Ordinary
Share is calculated by adjusting the weighted average number of
Ordinary shares outstanding to consider the impact of options,
warrants and other dilutive securities.
10
Investments at fair value through profit or loss
|
Level
1
|
Level
2
|
Level
3
|
|
|
Equity
investments in quoted companies
|
Equity
investments in unquoted companies
|
Debt
investments in unquoted companies
|
Equity
investments in unquoted companies
|
Debt
investments in unquoted companies
|
Total
|
GROUP
|
£
|
£
|
£
|
£
|
£
|
£
|
At
1 April 2022
|
1,133,854
|
-
|
-
|
3,803,301
|
-
|
4,937,155
|
Additions at Cost
|
1,177,139
|
-
|
-
|
650,656
|
-
|
1,827,795
|
Disposals at Cost
|
(257,490)
|
-
|
-
|
-
|
-
|
(257,490)
|
Amount owed to creditors
|
-
|
-
|
-
|
(6,801)
|
-
|
(6,801)
|
Change in Fair Value
|
(41,626)
|
-
|
-
|
2,999,291
|
-
|
2,957,665
|
At
1 April 2023
|
2,011,877
|
-
|
-
|
7,446,447
|
-
|
9,458,324
|
Additions at Cost
|
382,516
|
-
|
-
|
150,000
|
-
|
532,516
|
Disposals at Cost
|
(296,384)
|
-
|
-
|
(912,272)
|
-
|
(1,208,656)
|
Amount owed to creditors
|
-
|
-
|
-
|
(24,201)
|
-
|
(24,201)
|
Change in Fair Value
|
(483,914)
|
-
|
-
|
(1,773,379)
|
-
|
(2,257,293)
|
Impairment
|
-
|
-
|
-
|
(4,847,349)
|
-
|
(4,847,349)
|
At
31 March 2024
|
1,614,095
|
-
|
-
|
39,246
|
-
|
1,653,341
|
Included in the balance above are
investments that would be owed to the British Business Bank through
the Revenue Share Agreement. At the year end, an amount of £41
would be due to the British Business Bank on disposal. This
liability is shown in the accounts within other
creditors.
|
Level
1
|
Level
2
|
Level
3
|
|
|
Equity
investments in quoted companies
|
Equity
investments in unquoted companies
|
Debt
investments in unquoted companies
|
Equity
investments in unquoted companies
|
Debt
investments in unquoted companies
|
Total
|
COMPANY
|
£
|
£
|
£
|
£
|
£
|
£
|
At
1 April 2022
|
1,133,854
|
-
|
-
|
3,758,693
|
-
|
4,892,547
|
Additions at Cost
|
1,177,139
|
-
|
-
|
650,717
|
-
|
1,827,856
|
Disposal at Cost
|
(257,490)
|
-
|
-
|
-
|
-
|
(257,490)
|
Change in Fair Value
|
(41,626)
|
-
|
-
|
3,002,195
|
-
|
2,960,569
|
At
31 March 2023
|
2,011,877
|
-
|
-
|
7,411,605
|
-
|
9,423,482
|
Additions at Cost
|
382,516
|
-
|
-
|
150,000
|
-
|
532,516
|
Disposal at Cost
|
(296,384)
|
-
|
-
|
(912,272)
|
-
|
(1,208,656)
|
Change in Fair Value
|
(483,914)
|
-
|
-
|
(1,762,756)
|
-
|
(2,246,670)
|
Impairment
|
-
|
-
|
-
|
(4,847,349)
|
-
|
(4,847,349)
|
At
31 March 2024
|
1,614,095
|
-
|
-
|
39,228
|
-
|
1,653,323
|
As at 31 March 2024, the group total
value of investments in companies was £1,653,341 (2023:
£9,458,324).
The group total change in fair value
during the year was a loss of £2,257,293 (2023: profit £2,957,665).
There were impairments to investments in the year of £4,847,349
(2023: £Nil).
Investments, which is made up of
equity investments, are designated on initial recognition as
financial assets at fair value through profit or loss. This
measurement basis is consistent with the fact that the Group's
performance in respect of its portfolio investments is evaluated on
a fair value basis in accordance with an established investment
strategy. When investments are recognised initially, they are
measured at fair value.
After initial recognition the fair
value of listed investments is determined by reference to bid
prices at the close of business on the reporting date. Unlisted
equity investments are measured at fair value by the directors in
compliance with the principles of the International Private Equity
and Venture Capital Guidelines, updated and effective December
2015, as recommended by the European Venture Capital Association.
The fair value of unlisted equity investments is determined using
the most appropriate of the valuation methodologies set out in the
guidelines. These include using recent arm's length market
transactions; reference to the current market value of another
instrument, which is substantially the same; earnings or profit
multiples; indicative offers; discounted cash flow analysis and
pricing models.
The Group classifies its investments
using a fair value hierarchy. Classification within the hierarchy
has been determined on the basis of the lowest level input that is
significant to the fair value measurement of the relevant
investment as follows:
· Level 1 - valued using quoted prices in active markets for
identical assets;
· Level 2 - valued by reference to valuation techniques using
observable inputs other than quoted prices included within Level 1;
and
· Level 3 - valued by reference to valuation techniques using
inputs that are not based on observable market data.
The fair values of quoted
investments are based on bid prices in an active market at the
reporting date. All unquoted investments have been classified as
Level 3 within the fair value hierarchy, their respective
valuations having been calculated using a number of valuation
techniques and assumptions, notwithstanding that the
basis of the valuation methodology preferred by
the Group is 'price of most recent investment'. To reflect the potential
impact of alternative assumptions and a lack of liquidity in these
holdings, a discount has been applied to all Level 3
valuations. When using the DCF valuation
method, reasonably possible alternative assumptions could have a
material effect on the fair valuation of investments.
The methodologies used in the year
for level 3 investments are broken down as follows:
Methodology
|
Description
|
Inputs
|
Adjustments
|
% of portfolio valued on
this basis
|
Fund Raising
|
Used for unquoted investments
where there has been a funding round, generally within the last
twelve months
|
The price of the most recent
investment
|
A liquidity discount is applied,
typically 15%. Where last funding round is greater than twelve
months then further discounts ranging between 0% and 100% are
applied.
|
100%
|
Debt/Loan notes
|
Loan investments
|
The fair value of debt investment
is deemed to be cost less any impairment provision
|
Impairment provision if deemed
necessary
|
0%
|
Discounted cash flow and revenue
multiples
|
Used for companies with long-term
cash flows and having comparable transactions/ companies in the
listed segment
|
Long term cash flows are
discounted at a rate considered appropriate for the business,
typically 25%. Revenue multiples are typically 5 to 10 times of
forward looking revenue.
|
A liquidity discount is applied,
typically 20%
|
0.0%
|
Change in fair value in the
year:
|
|
Group
2024
|
Group
2023
|
|
|
|
£
|
£
|
|
Fair value gains
|
|
131,150
|
4,722,538
|
|
Fair value losses
|
|
(2,388,443)
|
(1,764,873)
|
|
|
|
(2,257,293)
|
2,957,665
|
|
|
|
|
|
|
|
|
|
The gain in the year came from the
uplift of the valuation in Autins. The main reasons for the fair
value losses were due to the disposal in Phase Focus Holdings
(£1,740,000) and the reduction in value in Aukett (£506,000),
Imaging Scan (£66,000), Velocity Composites (£44,000), Ryboquin
(£3,000) and Dimensional Imaging (£29,000).
Details of investments where the
nominal value of the holding in the undertaking is 20% or more of
any class of share are as follows:
Caledonia Portfolio Realisations
Limited ('CPR') holds a 20% aggregate shareholding in
Verbalis Limited ('Verbalis'), a design and
production of automated language translation systems
company. Neither CPR nor the Company is
represented on the Board or within management of Verbalis and in
the opinion of the directors, this shareholding does not entitle
the Company to exert a significant or dominant influence over
Verbalis. The carrying value of Verbalis is £nil (2023:
£nil).
The Company holds a 100% aggregate
holding in Paraytec Limited, which develops high performance
specialist detectors for the analytical and life sciences
instrumentation market. The valuation of Paraytec has been reviewed
and, for the reasons are detailed in the CEO statement the
valuation of Braveheart's investment has been impaired to zero. The
Company is represented on the board. The carrying value of Paraytec
£Nil (2023: £3,038,625).
The Company holds a 86% aggregate
holding in Kirkstall Limited, a biotechnology company which
developed a system of interconnected chambers for cell and tissue
culture in laboratories. The valuation of Kirkstall has been
reviewed and, for the reasons are detailed in the CEO statement the
valuation of Braveheart's investment has been impaired to zero. The
Company is represented on the Board. The carrying value of
Kirkstall is £Nil (2023: £1,674,845).
The Company holds a 38% aggregate
holding on Sentinel Medical Limited, this
company is developing a point of care
diagnostic device for bladder cancer detection and
monitoring. The
Company is represented on the Board and in the opinion of the
directors, this shareholding nor the representative entitles the
Company to exert a significant or dominant influence over Sentinel.
The carrying value of Sentinel is £33 (2023: £33).
The Company holds a 38.65%
aggregate holding in KDS Architecture Limited, a company which
provides architectural services. The Company is not represented on
the Board or within management of KDS Architecture and in the
opinion of the directors, this shareholding does not entitle the
Company to exert a significant or dominant influence over KDS
Architecture. The carrying value of KDS Architecture is £Nil (2023:
£76,074).
The registered addresses for these
entities are as follows:
Verbalis
Limited
Frostineb Cottage, Fala, Pathhead, Midlothian, Scotland, EH37
5TB
Paraytec
Limited
York House, Outgang Lane, Osbaldwick, York, England, YO19
5UP
Kirkstall Limited
York House, Outgang Lane, Osbaldwick, York, England, YO19
5UP
Sentinel Medical
Limited
York House, Outgang Lane,
Osbaldwick, York, England, YO19 5UP
KDS Architecture Limited
42 Lytton Road, Barnet,
England, EN5 5BY
11 Investment in subsidiaries
The Company has the following
interests in subsidiary undertakings:
Name
|
Country of Incorporation
|
Nature of Business
|
%
Interest
|
|
|
|
|
Caledonia Portfolio Realisations
Limited (i)
|
Scotland
|
Investment management
|
100%
|
Braveheart Academic Seed Funding GP
Limited (i)
|
England
|
Investment management
|
100%
|
Ridings Holdings Limited
(i)
|
England
|
Investment management
|
100%
|
The Ridings Early Growth Investment
Company Limited (ii)
|
England
|
Investment management
|
100%
|
Paraytec Limited (iii)
|
England
|
Development of high performance
specialist detectors
|
100%
|
Kirkstall Limited (iii)
|
England
|
Biotechnology
|
86%
|
Combrook Holdings
|
England
|
Investment management
|
60%
|
(i)
Direct subsidiary of Braveheart Investment Group
plc
(ii) Indirect subsidiary of Braveheart Investment Group
plc
(iii) Not consolidated
|
|
|
|
Group entities act as General
Partner to, and have an interest in, the following limited
partnerships:
Name
|
Place of
Business
|
%
Interest
|
|
|
|
Lachesis Seed Fund
|
England
|
0%
|
The registered addresses for the
subsidiary undertakings are as follows:
Caledonia Portfolio Realisations
Limited
1 George Square, Glasgow, Scotland, G2 1AL
Braveheart Academic Seed Funding GP
Limited
One Fleet Place, London, EC4M 7WS
Ridings Holdings
Limited
One Fleet Place, London, EC4M 7WS
The Ridings Early Growth Investment
Company Limited
One Fleet Place, London, EC4M 7WS
Paraytec
Limited
York House, Outgang Lane, Osbaldwick, York, North Yorkshire, YO19
5UP
Kirkstall
Limited
York House, Outgang Lane, Osbaldwick, York, North Yorkshire, YO19
5UP
Combrook Holdings
Limited
Old
Linen Court, 83-85 Shambles Street, Barnsley, South Yorkshire,
England,
S70
2SB
12
Property, plant and equipment
GROUP
|
Furniture, fittings and
equipment
|
Total
|
|
£
|
£
|
Cost
- At 31 March 2022
|
1,135
|
1,135
|
Additions
|
-
|
-
|
Cost
- At 31 March 2023
|
1,135
|
1,135
|
Additions
|
-
|
-
|
Cost
- At 31 March 2024
|
1,135
|
1,135
|
Depreciation - At 31 March 2022
|
339
|
339
|
Depreciation
|
378
|
378
|
Depreciation - 31 March 2023
|
717
|
717
|
Depreciation
|
310
|
310
|
Depreciation - 31 March 2024
|
1,027
|
1,027
|
Net
Book Value - At 1 April 2024
|
108
|
108
|
|
|
|
Net
Book Value - At 1 April 2023
|
418
|
418
|
COMPANY
|
|
Furniture, fittings and
equipment
|
Total
|
|
|
£
|
£
|
Cost
- At 31 March 2022
|
|
1,135
|
1,135
|
Additions
|
|
-
|
-
|
Cost
- At 31 March 2023
|
|
1,135
|
1,135
|
Additions
|
|
-
|
-
|
Cost
- At 31 March 2024
|
|
1,135
|
1,135
|
Depreciation - 31 March 2022
|
|
339
|
339
|
Depreciation
|
|
378
|
378
|
Depreciation - 31 March 2023
|
|
717
|
717
|
Depreciation
|
|
310
|
310
|
Depreciation - 31 March 2023
|
|
1,027
|
1,027
|
Net
Book Value - At 1 April 2024
|
|
108
|
108
|
|
|
|
|
Net
Book Value - At 1 April 2023
|
|
418
|
418
|
13 Debtors due in over one year
|
|
|
|
|
|
Group
|
Group
|
Company
|
Company
|
|
2024
|
2023
|
2024
|
2023
|
|
£
|
£
|
£
|
£
|
Amounts due from investment
companies
|
-
|
1,155,200
|
-
|
1,155,200
|
|
-
|
1,155,200
|
-
|
1,155,200
|
During the year,
the Board had concluded that Paraytec's short-term
prospects have reduced and it no longer believes
that Braveheart's outstanding loans
to Paraytec will be repaid in the short-term. A decision has therefore
been made to write down the value of the
Company's loan receivable in Paraytec
to £Nil.
14 Trade and other receivables
|
|
|
|
|
|
Group
|
Group
|
Company
|
Company
|
|
2024
|
2023
|
2024
|
2023
|
|
£
|
£
|
£
|
£
|
Trade receivables
|
31,899
|
31,126
|
-
|
2,471
|
Prepayments and accrued
income
|
73,808
|
22,632
|
73,808
|
22,632
|
Amounts due from related
parties
|
-
|
-
|
5,331
|
111,132
|
Amounts due from investment
companies
|
-
|
10,752
|
-
|
10,752
|
|
105,707
|
64,510
|
79,139
|
146,987
|
|
|
|
|
|
As trade receivables are generally
of short-term maturity, the directors consider the carrying amounts
to approximate their fair value. All receivables are non-interest
bearing and unsecured.
15 Cash and cash equivalents
|
|
|
|
|
|
Group
|
Group
|
Company
|
Company
|
|
2024
|
2023
|
2024
|
2023
|
|
£
|
£
|
£
|
£
|
Cash at bank and on hand
|
1,742,315
|
934,861
|
1,736,428
|
684,532
|
Cash balances are held with HSBC
Bank plc and earn interest at floating rates based on daily bank
deposit rates.
16
Trade and other payables
|
|
|
|
|
|
Group
|
Group
|
Company
|
Company
|
|
2024
|
2023
|
2024
|
2023
|
|
£
|
£
|
£
|
£
|
Trade payables
|
8,862
|
15,833
|
8,862
|
15,833
|
Amounts due to related
parties
|
-
|
-
|
168,968
|
30,472
|
Other taxes and social
security
|
15,061
|
32,093
|
13,994
|
30,968
|
Accruals and other
creditors
|
80,222
|
101,730
|
73,977
|
71,284
|
|
104,145
|
149,656
|
265,801
|
148,557
|
Due to the short-term maturity of
trade payables, the directors consider the carrying amounts to
approximate their fair value. Trade payables are non-interest
bearing and are normally settled on 30-day terms.
17
Deferred tax
The
following are the major deferred tax liabilities and assets
recognised by the company and movements thereon:
Balances
|
Group
|
Group
|
Company
|
Company
|
|
2024
|
2023
|
2024
|
2023
|
|
£
|
£
|
£
|
£
|
Non current asset investment timing
differences
|
-
|
944,050
|
-
|
944,050
|
|
-
|
944,050
|
-
|
944,050
|
Movements in the year
|
|
|
Group
|
Company
|
|
|
|
£
|
£
|
Liability at 1 April 2023
|
|
|
944,050
|
944,050
|
Charge to profit and loss
|
|
|
(944,050)
|
(944,050)
|
Liability at 31 March
2024
|
|
|
-
|
-
|
All deferred tax liabilities will be
settled, in greater than one year.
18
Share capital
|
|
2024
|
2023
|
|
|
£
|
£
|
Authorised
|
|
|
|
68,674,431 ordinary shares of 2
pence each
(2023: 68,674,431 ordinary shares of
2 pence each)
|
|
1,373,489
|
1,373,489
|
|
|
|
|
Allotted, called up and fully
paid
|
|
|
|
63,723,489 ordinary shares of 2
pence each
(2023: 63,723,489 ordinary shares of
2 pence each)
|
|
1,274,469
|
1,274,469
|
The Company has one class of
ordinary shares. All shares carry equal voting rights, equal rights
to income and distribution of assets on liquidation or otherwise,
and no right to fixed income.
Reconciliation of movements during the year
|
|
Share
Premium
|
Share
Capital
|
At
1 April 2023
|
|
5,370,711
|
1,274,469
|
Issue of fully paid
shares
|
|
-
|
-
|
Cost of shares issued
|
|
-
|
-
|
At
31 March 2024
|
|
5,370,711
|
1,274,469
|
Reconciliation of share movements during the
year
At
1 April 2023
|
|
|
63,723,489
|
Issue of fully paid
shares
|
|
|
-
|
At
31 March 2024
|
|
|
63,723,489
|
19
Share-based
payments
Share Option Scheme
On 17 December 2020, the company
created a share scheme in order to provide a long term incentive
plan for the directors, employees and consultants of the group "the
Share Option Plan".
2020 Award
On 17 December 2020 a number of
directors, employees and consultants were awarded 2,350,000 shares
at an exercise price of £0.17. There were no conditions attached to
these and they expire 10 years from the date of grant. The share
based payment was worked out on the Black Scholes model. The
following information is relevant in the determination of the fair
value of options granted under the 2020 award.
Grant
date
17/12/2020
Number of
awards
2,350,000
Share
price
£0.17
Exercise
price
£0.17
Expected dividend
yield
-
Expected
volatility
171.74%
Risk free
rate
0.40%
Vesting
period
10 years
Expected life (from date of
grant)
1.5 years
The share based payment charge for
the year ended 31 March 2024 was £Nil (2023: £Nil).
2021 Award
On 13 October 2021 two directors
were awarded 3,500,000 shares at an exercise price of
£0.315. The options vest
on 14 October 2022 and are exercisable up to 14 October 2031. The options
are also subject to performance criteria under which the options
can only be exercised if the average share price over a 30
consecutive calendar day period has been 20 per cent. higher than
the option exercise price. The share based
payment was worked out on the Monte Carlo model. The following
information is relevant in the determination of the fair value of
options granted under the 2020 award.
Grant
date
14/10/2021
Number of
awards
3,500,000
Share
price
£0.315
Exercise
price
£0.315
Expected dividend
yield
-
Expected
volatility
69.27%
Risk free
rate
0.372%
Vesting
period
10 years
Expected life (from date of
grant)
1 year
On 9 May 2022, 1,500,000 were
cancelled and replaced with shares under new
conditions. The exercise price of
the New Options is 14p, being the closing mid-market price of an
Ordinary Share on 6 May
2022, the latest practicable date prior to
the date of grant. The New Options will vest
from 9 May 2023 and be exercisable up to 9
May 2032, subject to continued employment
and an additional performance related criteria that the closing
price of an Ordinary Share must exceed 31.5p, being the exercise
price of the Historic Options, for 10 days within any period of 30
days. The share based payment was worked out under the Monte Carlo
model and didn't result in a share based payment charge.
The share based payment charge for
the year ended 31 March 2024 was £81,289 (2023:
£208,645).
2023 Award
On 27 March 2023, a further
2,500,000 were granted to two board members and could be vested
over the next 12 months, once certain performance criteria were
met. As these were market related, the Monte Carlo model was used.
A further 450,000 shares were granted to two board members and one
other person not on the board. There were no performance conditions
attached to these options.
The following information is
relevant in the determination of the fair value of options granted
under the 2020 award.
Shares with
options
Shares without options
Grant
date
27/03/2023
27/03/2023
Number of
awards
2,500,000
450,000
Share
price
£0.078
£0.078
Exercise
price
£0.078
£0.078
Expected dividend
yield
-
-
Expected
volatility
50.91%
50.91%
Risk free
rate
5.10%
5.10%
Vesting
period
10
years
10 years
Expected life (from date of
grant)
1.5
years
1.5 years
The share based payment charge for
the year ended 31 March 2024 was £45,696 (2023: £10,578)
The total share based payment charge
for all schemes in the year was £126,985 (2023:
£219,223)
Share Options arising from the New Scheme
The current year movement in Share
Options is summarised below:
|
Date of
Grant
|
At
1
April
2023
|
No of
Options granted in year
|
No of
Options exercised in year
|
No of
Options lapsed in year
|
At 31
March 2024
|
Exercise
Price
|
Date
first
exercisable
|
Expiry
date
|
Employment Options granted
|
|
|
|
|
|
|
|
|
|
|
|
17 Dec
2020
|
1,096,000
|
-
|
-
|
-
|
1,096,000
|
£0.17
|
17 Dec
2020
|
16 Dec
2030
|
|
14 Oct
2021
|
2,976,192
|
-
|
-
|
-
|
2,976,192
|
£0.315
|
14 Oct
2022
|
14 Oct
2031
|
|
27 Mar
2023
|
2,900,000
|
-
|
-
|
-
|
2,900,000
|
£0.0775
|
27 Mar
2024
|
27 Mar
2033
|
|
27 Mar
2023
|
50,000
|
-
|
-
|
-
|
50,000
|
£0.0775
|
27 Mar
2023
|
27 Mar
2033
|
|
|
7,022,192
|
-
|
-
|
-
|
7,022,192
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The weighted average price was £0.19
(2023: £0.19). At the year end, the number of exercisable shares
were 7,022,192 (2023: 7,022,192) with a weighted life of 8.02 years
(2023: 9.02 years).
The previous year movement in Share
Options is summarised below:
|
Date of
Grant
|
At
1
April
2022
|
No of
Options granted in year
|
No of
Options exercised in year
|
No of
Options lapsed in year
|
At 31
March 2023
|
Exercise
Price
|
Date
first
exercisable
|
Expiry
date
|
Employment Options granted
|
|
|
|
|
|
|
|
|
|
|
|
17 Dec
2020
|
1,096,000
|
-
|
-
|
-
|
1,096,000
|
£0.17
|
17 Dec
2020
|
16 Dec
2030
|
|
14 Oct
2021
|
3,500,000
|
|
-
|
(523,808)
|
2,976,192
|
£0.315
|
14 Oct
2022
|
14 Oct
2031
|
|
27 Mar
2023
|
-
|
2,900,000
|
-
|
-
|
2,900,000
|
£0.0775
|
27 Mar
2024
|
27 Mar
2033
|
|
27 Mar
2023
|
-
|
50,000
|
-
|
-
|
50,000
|
£0.0775
|
27 Mar
2023
|
27 Mar
2033
|
|
|
4,596,000
|
2,950,000
|
-
|
(523,808)
|
7,022,192
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The charge made in respect of the
fair value of options granted was:
|
|
2024
|
2023
|
|
|
£
|
£
|
Expense arising from
equity-settled share-based payments transactions
|
|
126,985
|
219,223
|
20
Related party disclosures
Trade and other receivables (note
14) include the following amounts due from subsidiary
undertakings:
|
|
|
2024
£
|
2023
£
|
The Ridings Early Growth Investment
Company Limited
|
|
|
-
|
105,504
|
Braveheart Academic Seed
Funding
|
|
|
5,331
|
5,628
|
|
|
|
5,331
|
111,132
|
Trade and other payables (note 16)
include the following amounts due to subsidiary
undertakings:
|
|
|
2024
£
|
2023
£
|
Ridings Holdings Limited
|
|
|
119,412
|
30,412
|
Caledonia Portfolio
Realisations
|
|
|
15,000
|
-
|
The Ridings Early Growth Investment
Company Limited
|
|
|
34,496
|
-
|
Combrook Holdings Limited
|
|
|
60
|
60
|
|
|
|
168,968
|
30,472
|
All above amounts are unsecured,
interest free and repayable on demand. Transactions between the
Company and its subsidiaries are eliminated on consolidation.
The Directors have agreed that,
while amounts due to Group companies are included in trade and
other payables due within one year as they are technically payable
on demand, payment of these amounts will not be required unless the
company is able to do so.
During the year, Braveheart charged
the Ridings Early Growth Investment Company Ltd £Nil (2023: £Nil)
in respect of a management charge. During the year, Braveheart
Investment Group Plc generated revenue of £17,296 (2023: £32,302)
from The Lachesis Seed Fund Limited
Partnership, a General Partner that the group have an interest
in.
During the year, Braveheart
charged Kirkstall Limited £26,667 (2023: £15,000) in respect of a
management charge. The balance owed
to Braveheart at year end was £164,354 (2023: £10,752) although
this was impaired to £Nil at the year end. During the year, the Board had
concluded that Kirkstall's
short-term prospects
have reduced and
it no longer believes that Braveheart's outstanding loans to Kirkstall
will be repaid in the short-term. A decision has therefore been made to write down the value
of the Company's loan receivable in Kirkstall to £Nil.
During the year, Braveheart
charged Paraytec Limited £13,333 (2023: £Nil) in respect of a
management charge. At the year end,
Paraytec owed Braveheart £1,438,200 (2023: £1,155,200).
During the year, the
Board had concluded that Paraytec's
short-term prospects
have reduced and
it no longer believes that Braveheart's outstanding loans to Paraytec
will be repaid in the short-term. A decision has therefore been made to write down the value
of the Company's loan receivable in Paraytec to £Nil.
Non-Executive Director, Qu Li, is
also a Director and major shareholder of Agile Impact Capital Ltd.
During the year Agile Capital Impact Ltd charged the Braveheart
Investment Group plc a total of £35,118 (2023: £31,750) in respect
of services provided by Dr Li. The balance outstanding at year end
was £Nil (2023: £3,300).
21
Financial risk management objectives and policies (Group and
Company)
The Group and Company's financial
instruments comprise investments designated at fair value through
profit or loss, cash and various items such as trade and other
receivables, and trade and other payables, all of which arise
directly from its normal operations.
The carrying values of all of the
Group and Company's financial instruments approximate their fair
values at 31 March 2024 and 31 March 2023. The Accounting Policies
described in note 2 outlines how the financial instruments are
measured.
An analysis of the statement of
financial position, relevant to an analysis of risk management, is
as follows:
|
Financial
instruments
|
|
|
|
Designated at fair value
though profit or loss
|
Loans and receivables at
amortised cost
|
Non-financial assets &
financial assets outside the scope of IFRS 9
|
Total
|
|
£
|
£
|
£
|
£
|
GROUP
|
|
|
|
|
2024
|
|
|
|
|
Investments
|
1,653,341
|
-
|
-
|
1,653,341
|
Trade and other
receivables
|
-
|
20,071
|
85,636
|
105,707
|
Cash and cash equivalents
|
-
|
1,742,315
|
-
|
1,742,315
|
|
1,653,341
|
1,762,386
|
85,636
|
3,501,363
|
|
|
|
|
|
2023
|
|
|
|
|
Investments
|
9,458,324
|
-
|
-
|
9,458,324
|
Trade and other
receivables
|
-
|
1,197,078
|
22,632
|
1,219,710
|
Cash and cash equivalents
|
-
|
934,861
|
-
|
934,861
|
|
9,458,324
|
2,131,939
|
22,632
|
11,612,895
|
COMPANY
|
|
|
|
|
2024
|
|
|
|
|
Investments
|
1,653,323
|
-
|
-
|
1,653,323
|
Trade and other
receivables
|
-
|
20,071
|
59,068
|
79,139
|
Cash and cash equivalents
|
-
|
1,736,428
|
-
|
1,736,428
|
|
1,653,323
|
1,756,499
|
59,068
|
3,468,890
|
|
|
|
|
|
2023
|
|
|
|
|
Investments
|
9,423,482
|
-
|
-
|
9,423,482
|
Trade and other
receivables
|
-
|
1,279,555
|
22,632
|
1,302,187
|
Cash and cash equivalents
|
-
|
684,532
|
-
|
684,532
|
|
9,423,482
|
1,964,087
|
22,632
|
11,410,201
|
|
|
|
|
|
21
Financial risk management objectives and policies (Group and
Company) (continued)
|
|
Other financial liabilities
at amortised cost
|
Financial liabilities at
fair value
|
Total
|
|
|
£
|
£
|
£
|
GROUP
|
|
|
|
|
2024
|
|
|
|
|
Trade and other payables
|
|
104,145
|
-
|
104,145
|
Borrowings
|
|
-
|
-
|
-
|
|
|
104,145
|
-
|
104,145
|
|
|
|
|
|
2023
|
|
|
|
|
Trade and other payables
|
|
149,656
|
-
|
149,656
|
Borrowings
|
|
-
|
-
|
-
|
|
|
149,656
|
-
|
149,656
|
|
|
|
|
|
COMPANY
|
|
|
|
|
2024
|
|
|
|
|
Trade and other payables
|
|
265,801
|
-
|
265,801
|
|
|
265,801
|
-
|
265,801
|
|
|
|
|
|
2023
|
|
|
|
|
Trade and other payables
|
|
148,557
|
-
|
148,557
|
|
|
148,557
|
-
|
148,557
|
One of the Group's principal
objectives and policies is to achieve income and capital gains
through investment in equity shares in a portfolio of UK companies,
the majority of which are unlisted.
Through its normal operations the
Group is exposed to a number of financial risks, namely credit
risk, liquidity risk and market risk. The Board reviews and agrees
policies for managing each of these risks as summarised
below.
Credit risk
Credit risk arises from the
exposure to the risk of loss if the counterparty fails to perform
its financial obligations to the Group. The Group's financial
assets predominantly comprise investments designated at fair value
through profit or loss, and cash. In accordance with its
Investment Policy, the Group seeks to manage credit risk related to
its investments through detailed investment selection criteria and
diversification and by placing limits on individual investments. In
accordance with its Treasury Policy, the Group seeks to mitigate
this risk on cash by placing funds only
with banks with high credit-ratings assigned by international
credit-rating agencies.
The Group has no significant
concentration of credit risk within any of its other financial
assets. Included within such other financial assets are
balances which are past due at the
reporting date for which the Group has not provided as there has
not been a significant change in their credit quality and which the
Group believes are fully recoverable. The
age profile of the Group and Company's other financial assets is as
follows:
|
|
Neither past due nor
impaired
|
Less than 3
months
|
3 to 12
months
|
More than 1
year
|
Total
|
|
|
£
|
£
|
£
|
£
|
£
|
GROUP
|
|
|
|
|
|
|
2024
|
|
|
|
|
|
|
Trade receivables
|
|
8,199
|
-
|
1,800
|
21,900
|
31,899
|
Other receivables
|
|
73,808
|
-
|
-
|
-
|
73,808
|
|
|
82,007
|
-
|
1,800
|
21,900
|
105,707
|
|
|
|
|
|
|
|
2023
|
|
|
|
|
|
|
Trade receivables
|
|
5,355
|
5,071
|
2,400
|
18,300
|
31,126
|
Other receivables
|
|
1,188,584
|
-
|
-
|
-
|
1,188,584
|
|
|
1,193,939
|
5,071
|
2,400
|
18,300
|
1,219,710
|
|
|
|
|
|
|
|
COMPANY
|
|
|
|
|
|
|
2024
|
|
|
|
|
|
|
Trade receivables
|
|
-
|
-
|
-
|
-
|
-
|
Other receivables
|
|
73,808
|
-
|
-
|
-
|
73,808
|
Amounts due from related
parties
|
|
5,331
|
-
|
-
|
-
|
5,331
|
Amounts due from investment
companies
|
|
-
|
-
|
-
|
-
|
-
|
|
|
79,139
|
-
|
-
|
-
|
79,139
|
|
|
|
|
|
|
|
2023
|
|
|
|
|
|
|
Trade receivables
|
|
2,471
|
-
|
-
|
-
|
2,471
|
Other receivables
|
|
22,632
|
-
|
-
|
-
|
22,632
|
Amounts due from related
parties
|
|
111,132
|
-
|
-
|
-
|
111,132
|
Amounts due from investment
companies
|
|
1,165,952
|
-
|
-
|
-
|
1,165,952
|
|
|
1,302,187
|
-
|
-
|
-
|
1,302,187
|
|
|
|
|
|
|
|
The Group considers its exposure to
credit risk is negligible. The Group's bank balance of
£1,742,315 at the
year-end is held in a bank with a high credit rating and the trade
and other receivables of £105,707 are closely monitored as part of
the credit control process.
Liquidity risk
Liquidity risk is the risk that
the Group will not be able to meet its financial obligations as
they fall due.
The Group seeks to manage its
liquidity risk by holding sufficient cash reserves to meet
foreseeable needs, and by investing cash assets safely. The Group
continuously monitors rolling cash flow forecasts to ensure
sufficient cash is available for anticipated cash requirements and,
in accordance with its Treasury Policy, the Group only invests cash
assets with reputable counterparties.
The maturity profile of the Group
and Company's financial liabilities is as follows:
|
On demand
|
Less than 3
months
|
3 to 12
months
|
More than 1
year
|
Total
|
|
£
|
£
|
£
|
£
|
£
|
GROUP
|
|
|
|
|
|
2024
|
|
|
|
|
|
Trade and other payables
|
102,782
|
925
|
438
|
-
|
104,145
|
|
102,782
|
925
|
438
|
-
|
104,145
|
|
|
|
|
|
|
2023
|
|
|
|
|
|
Trade and other payables
|
144,362
|
4,159
|
1,135
|
-
|
149,656
|
|
144,362
|
4,159
|
1,135
|
-
|
149,656
|
COMPANY
|
|
|
|
|
|
2024
|
|
|
|
|
|
Trade and other payables
|
95,470
|
925
|
438
|
-
|
96,833
|
Amounts due to related
parties
|
168,968
|
-
|
-
|
-
|
168,968
|
|
264,438
|
925
|
438
|
-
|
265,801
|
|
|
|
|
|
|
2023
|
|
|
|
|
|
Trade and other payables
|
112,791
|
4,159
|
1,135
|
-
|
118,085
|
Amounts due to related
parties
|
30,472
|
-
|
-
|
-
|
30,472
|
|
143,263
|
4,159
|
1,135
|
-
|
148,557
|
|
|
|
|
|
|
Market Risk
Market risk is the risk that changes
in market conditions such as equity prices, interest rates and
foreign exchange rates will have an adverse impact on the Group's
financial position or results.
Equity price
risk
The Group is exposed to equity price
risk due to uncertainties about future values of its portfolio of
listed and unlisted equity investments. The Group manages such
equity price risk in a similar way to credit risk through detailed
investment selection criteria and diversification and by placing
limits on individual investments. Investments are monitored carefully and the Board reviews the
portfolio on a regular basis.
Interest rate
risk
The Group finances its operations
through equity funding as opposed to debt and therefore minimises
its exposure to interest rate risks. The Group and Company's
financial instruments are non-interest bearing, with the exception
of loan notes which attract fixed rate interest, and cash balances
which attract variable interest rates determined with reference to
the bank interest rate.
The interest rate profile of the
Group and Company's financial instruments is as follows:
|
|
|
Fixed Rate
|
Variable
Rate
|
Interest
free
|
Total
|
GROUP
|
£
|
£
|
£
|
£
|
2024
|
|
|
|
|
Financial assets
|
|
|
|
|
Investments: equity
|
-
|
-
|
1,653,341
|
1,653,341
|
Cash and cash equivalents
|
-
|
1,742,315
|
-
|
1,742,315
|
Other financial assets
|
-
|
-
|
105,707
|
105,707
|
|
-
|
1,742,315
|
1,759,048
|
3,501,363
|
|
|
|
|
|
Financial liabilities
|
|
|
|
|
Other financial
liabilities
|
-
|
-
|
104,145
|
104,145
|
|
-
|
-
|
104,145
|
104,145
|
|
|
|
|
|
2023
|
|
|
|
|
Financial assets
|
|
|
|
|
Investments: equity
|
-
|
-
|
9,458,324
|
9,458,324
|
Cash and cash equivalents
|
-
|
934,861
|
-
|
934,861
|
Other financial assets
|
-
|
-
|
1,219,710
|
1,219,710
|
|
-
|
934,861
|
10,678,034
|
11,612,895
|
|
|
|
|
|
Financial liabilities
|
|
|
|
|
Other financial
liabilities
|
-
|
-
|
149,656
|
149,656
|
|
-
|
-
|
149,656
|
149,656
|
Interest rate
risk
|
|
|
Fixed Rate
|
Variable
Rate
|
Interest
free
|
Total
|
COMPANY
|
£
|
£
|
£
|
£
|
2024
|
|
|
|
|
Financial assets
|
|
|
|
|
Investments: equity
|
-
|
-
|
1,653,323
|
1,653,323
|
Cash and cash equivalents
|
-
|
1,736,428
|
-
|
1,736,428
|
Other financial assets
|
-
|
-
|
79,139
|
79,139
|
|
-
|
1,736,428
|
1,732,462
|
3,468,890
|
Financial liabilities
|
|
|
|
|
Other financial
liabilities
|
-
|
-
|
265,801
|
265,801
|
|
-
|
-
|
265,801
|
265,801
|
|
|
|
|
|
2023
|
|
|
|
|
Financial assets
|
|
|
|
|
Investments: equity
|
-
|
-
|
9,423,482
|
9,423,482
|
Cash and cash equivalents
|
-
|
684,532
|
-
|
684,532
|
Other financial assets
|
-
|
-
|
1,302,187
|
1,302,187
|
|
-
|
684,532
|
10,725,669
|
11,410,201
|
Financial liabilities
|
|
|
|
|
Other financial
liabilities
|
-
|
-
|
148,557
|
148,557
|
|
-
|
-
|
148,557
|
148,557
|
It is estimated that the maximum
effect of a one percentage point (100 basis points) fall in
interest rates to which the Group is exposed would be a decrease in
profit before tax for the twelve months to 31 March 2024 of £17,423
(2023: £9,349). For the company, this would be £17,364 (2023:
£6,845).
Foreign currency
risk
The Group has no material exposure
to foreign currency risk.
22 Ultimate controlling party
There is no ultimate controlling
party.